Figure 1.

Preclinical study treatment strategy in Emilin1‐deficient mouse model of AVD. Emilin1 deficiency results in early p‐Erk1/2, elastase and Vegf activation at 4 month followed by the manifestation of AVD, characterized by fibrosis, neovascularization, and inflammation, at 12 months of age and premature death at 15–18 months of age. Treatment was initiated at 12 month age (arrow) and all five treatment groups were treated for 1 month period using drugs as mentioned.